ATHA Athira Pharma

Athira Pharma to Participate in Panel and Corporate Presentations at Life Science Innovation Northwest Conference

Athira Pharma to Participate in Panel and Corporate Presentations at Life Science Innovation Northwest Conference

BOTHELL, Wash., March 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that the company will participate in panel and corporate presentations at the virtual Life Science Innovation Northwest Conference taking place March 30-31, 2021.

Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a panel titled “New Treatments and Potential Cures in Alzheimer’s Disease and Neurodegeneration: The Future is Here!” at 12:30 p.m. PT on Tuesday, March 30. The discussion will be moderated by Paul Matteis, Managing Director at Stifel, and include participation from Valerie Daggett, Ph.D., Co-Founder and Chief Executive Officer at AltPep, and Carole Ho, M.D., Chief Medical Officer and Head of Development at Denali Therapeutics.

Kevin Church, Ph.D., will present a corporate overview as part of the Neuroscience & Discovery Platforms company presentations from 1:35 to 3:00 p.m. PT on Tuesday, March 30.

These events will be webcast live and available for access by registered conference attendees. For more information on registration, please visit:

About Athira Pharma, Inc.

Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit . You can also follow Athira on ,  and @athirapharma on  and .

Investor & Media Contact:

Julie Rathbun

Athira Pharma



206-769-9219



EN
23/03/2021

Underlying

ATHAAthira Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Athira Pharma

 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Off...

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer Brings more than 25 years of biopharma business development and corporate strategy expertise BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio’s business development strategy and execution, with responsibility for licensing, partn...

February 3, 2026 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker ...

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it has changed its name to LeonaBio, Inc. The name change aligns with the Company’s transforma...

January 9, 2026 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Deve...

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., De...

December 18, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Reports Third Quarter 2025 Financial Results and Provide...

Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value   Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable safety and tolerability profile as well as dose proportional pharmacokinetics and CNS penetration, supporting continued clinical development  BOTHELL, Wash., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Reverse Stock Split

Athira Pharma Announces Reverse Stock Split BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira’s issued and authorized common stock. Athira’s stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse st...

September 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch